Basic and clinical researchers from industry and academia detail the preclinical, clinical, and regulatory principles currently used to assess the cardiac safety of new drugs. The authors explain the parameters of cardiac safety at all stages of clinical research and drug development, including both the preclinical and pharmacogenomic aspects generally and the clinical methodologies and technical aspects for investigational drugs based on
cardiac repolarization, as defined by the duration of the QTc interval. Additional chapters comprehensively review the application of
electrocardiography in clinical research, the fundamentals of ECG interpretation in clinical trials, the statistical…
